Cerity Partners
TVTX icon

Cerity Partners’s Travere Therapeutics TVTX Stock Holding History

Cerity Partners’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.35M Buy
23,795
+13,912
+141% +$617K ﹤0.01% 1806
2026
Q1 		$294K Sell
9,883
-7,732
-44% -$231K ﹤0.01% 2628
2025
Q4 		$673K Buy
17,615
+9,100
+107% +$296K ﹤0.01% 1919
2025
Q3 		$204K Buy
+8,515
New +$160K ﹤0.01% 2498
2025
Q2 		– Sell
-12,101
Closed -$217K – 2760
2025
Q1 		$217K Buy
+12,101
New +$246K ﹤0.01% 2180
2024
Q4 		– Sell
-13,748
Closed -$192K – 2595
2024
Q3 		$192K Buy
+13,748
New +$143K ﹤0.01% 2330

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Cerity Partners's TVTX Position: Q2 2026 in Review

Cerity Partners increased its Travere Therapeutics (TVTX) stake by 141% in Q2 2026, buying an estimated $617K and bringing the position to 23,795 shares worth $1.35M. The position accounts for ﹤0.01% of the portfolio, ranked #1806.

Cerity Partners first reported a position in TVTX in Q3 2024 and has held it in 6 quarters since. 291 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Cerity Partners held 23,795 shares of Travere Therapeutics worth $1.35M as of Q2 2026.
  • Cerity Partners bought 13,912 Travere Therapeutics shares in Q2 2026, an estimated $617K.
  • Travere Therapeutics made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #1806 holding.
  • Cerity Partners first reported a position in Travere Therapeutics in Q3 2024 and has held it in 6 quarters since.
  • 291 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.